Asthma and breathing
Omalizumab and your FAA medical
IgE inhibitor, biologic
Other names: Xolair
Wait
2 weeks
ground trial when starting
Different waits apply in other cases.
FAA label
CONDITIONALLY ACCEPTABLE
The FAA lists omalizumab as conditionally acceptable, depending on the underlying condition, with a two-week ground trial when starting and 24 hours of no-fly after each dose.
Track your medicationsCompare FAA documents: omalizumabWhat each of the two FAA documents says, in plain wordsOpen
Wait
- 24 hours no-fly after each dose
- a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication
Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial.
The FAA's CACI – Asthma Worksheet says monoclonal antibodies are not acceptable for CACI; it does not name omalizumab.
- 14 days after starting: ground observation
- 24 hours after each dose: no flying
Show the FAA's words: omalizumabThe official FAA wording: three passages, each with its document and dateOpen
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
CONDITIONALLY ACCEPTABLE BIOLOGIC MEDICATIONS Monotherapy — Dependent on underlying condition(s), see those pages.
IgE Inhibitor: omalizumab (Xolair), 24 hours
Changing from one biologic/biosimilar to another for the same indication requires a forty-eight (48) hour ground trial to mitigate any aeromedical risk.
Acceptable Medications
NOT acceptable for CACI:
Monoclonal antibodies